ABOUT

The live virtual symposium, CAR-T IN LUPUS: A NEW ERA IN TREATMENT AND TRIAL ENGAGEMENT will provide foundational and practical education on CAR-T’s mechanism of action, its therapeutic potential in SLE, and the role of rheumatology providers in the treatment process. The session will be designed specifically for rheumatology APPs by rheumatology APPs and will deliver focused, didactic education on treatment optimization and therapeutic differentiation, preparing attendees to apply the latest evidence in their clinical practice before year’s end.

FACULTY

Elizabeth Kirchner, DNP

Cleveland Clinic

Cleveland, OH

Melissa Griffith, MD, RhMSUS
University of Colorado School of Medicine
Aurora, CO

AGENDA

January 29, 2026

8:00 – 8:05 PM Unmet Needs in SLE
8:05 – 8:15 PM CAR-T Mechanism, and Potential Role in SLE
8:15 – 8:25 PM CAR-T Cell Therapy Process and Journey
8:25 – 8:35 PM The Role of The Rheumatology Provider
8:35 – 8:45 PM Clinical Trial Landscape
8:45 – 8:55 PM Identifying Eligible Patients and Referring to
Oncology Clinical Trials (Review of CAR-T in
SLE: Point of Care Pocket Guide)
8:55 – 9:00 PM Q&A

ACCREDITATION INFORMATION

Program Overview

The live virtual symposium, CAR-T IN LUPUS: A NEW ERA IN TREATMENT AND TRIAL ENGAGEMENT will provide foundational and practical education on CAR-T’s mechanism of action, its therapeutic potential in SLE, and the role of rheumatology providers in the treatment process. The session will be designed specifically for rheumatology APPs by rheumatology APPs and will deliver focused, didactic education on treatment optimization and therapeutic differentiation, preparing attendees to apply the latest evidence in their clinical practice before year’s end.

Target Audience

This activity has been designed to meet the educational needs of APPs involved in the care of patients with systemic lupus erythematosus (SLE).

Educational Objectives

Upon completion of this educational activity, participants should be able to:

Describe the mechanism of action of CAR-T cell therapy and its investigational role in treating SLE
Explain the key steps in the CAR-T treatment process including the role of the rheumatology provider
Evaluate current clinical trials investigating CAR-T cell therapy in SLE and summarize their eligibility criteria
Apply referral strategies to identify appropriate patients for enrollment in SLE CAR-T clinical trials using available tools and checklists

Accreditation Statement:

In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and Rheumatology Advanced Practice Providers. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Associate Credit:

Medical Education Resources has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit(s). PAs should only claim credit commensurate with the extent of their participation.

Pharmacist Credit:

Medical Education Resources (MER) designates this continuing education activity for 1.0 contact hour (1.0 CEU) of the Accreditation Council for Pharmacy Education. (Universal Program Number – JA 0003680-9999-26-066-L01-P

This activity is certified as a knowledge-based CPE.

Nurse Credit:

Medical Education Resources designates live activity for a maximum of 1.0 ANCC nursing contact hour(s). Nurses will be awarded contact hours upon successful completion of the activity.

Disclosure of Relevant Financial Relationships:

Medical Education Resources (MER) ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies all financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported relevant financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality CE activities that promote improvements or quality in health care and not the business interest of an ineligible company.

MER and Rheumatology Advanced Practice Providers planners have no relevant financial relationships to disclose.

Disclaimer:

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, and Rheumatology Advanced Practice Providers and/or Bristol Myers Squibb. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

MER Privacy Policy: http://cmepartner.org/privacy

Fee Information: There is no fee for this educational activity.

Jointly provided by Medical Education Resources and Rheumatology Advanced Practice Providers.